Drug Companies Must Report Payments to Docs Under "Sunshine" Provisions to PPACA
Under a new federal reporting requirement, drug companies must now disclose all payments made to physicians – or else risk getting hit with hefty penalties.
The new “sunshine” provisions were included as part of the 2010 Patient Protection and Affordable Care Act, but proposed guidelines for reporting were not released until recently. The public will have until February 17 to comment on the proposals, after which time Medicare officials will issue final rules.
Under the guidelines, drugmakers and manufacturers of medical devices will have to report any payments made to physicians to develop, assess or promote new products. Royalty payments to doctors for inventions or discoveries, and payments to teaching hospitals for research or other activities will also have to be reported. (Payments to physicians who are employees of the device/drug manufacturer will not have to be reported.)
All payment data will be posted on a website where it will be available to the public. Companies who fail to properly report such payments face fines – the government will impose a penalty of $10,000 for each payment the company fails to report. A company that knowingly fails to report payments will be subject to a penalty up to $100,000 for each violation, up to a total of $1 million per year.
The “sunshine” reporting requirements were enacted out of concern that payments to physicians were skewing health care providers’ professional judgment and detracting from the patients’ best interests.